Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * Patients with CRC liver metastases (\< 3 lesions, \< 3 cm in diameter), proven on MRI and/or Positron Emission Tomography scan. * Patient eligible for thermoablation requiring CT guidance (at least one metastasis not visible on ultrasound). * Treatment by thermoablation validated in multidisciplinary meeting. * Eastern Cooperative Oncology Group performance score 0-2. * ASA score 1-3. * Life expectancy of more than 3 months. * Renal function allowing iodinated contrast injection (clearance \> 30 mL/min), normal liver function (bilirubin \< 35 µmol/L) and hemostasis assessment allowing percutaneous procedure (PT \> 50%, platelets \> 50 G/L, anticoagulant treatment to be stopped). * Postmenopausal patient or patient with effective contraception (hormonal or mechanical) * Pregnancy test (bHCG blood) negative in the month prior to inclusion for patients of childbearing age * Patients with a history of radical treatment (surgery, radiofrequency or stereotactic radiotherapy) for liver metastases more than 6 months old. * Patient presenting a recurrence at a distance from the treated lesion (more than 1 cm from the scar). Exclusion Criteria: * The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Lesion not eligible for thermoablation (proximity of the liver hilum and the main bile duct). * Uncorrectable abnormalities of liver or blood functions (coagulation). * Severe allergy to contrast media. * Contraindication to MRI (pacemaker, neuro-stimulator, cochlear implant, metallic heart valve, claustrophobia). * Uncontrolled infection. * Any physical, physiological or psychological condition incompatible with study participation or patient compliance. * Pregnant, parturient or nursing patient. * Contraindications mentioned in the Product Monographs of the following drugs: * FLUCIS: Hypersensitivity to the active substance (fludeoxyglucose (18F)) or to one of the excipients. * VISIPAQUE 320 * Hypersensitivity to the active substance or to any of the excipients mentioned in section 6.1. * History of immediate major or delayed cutaneous reaction (see section 4.8) to the injection of iodinated contrast material (Visipaque), * Decompensated cardiac insufficiency with systemic injection (only concerns high osmolarity ionic products), * Overt thyreotoxicosis, * Hysterosalpingography in pregnancy * patient with a history of radical treatment for liver metastases (surgery, thermoablation, stereotactic radiotherapy) less than 6 months old. * patient with recurrence within 1 cm of the scar.